BLUEWAVE™ technology represents a technological leap in the evolution of light therapy. For the first time, we are able to isolate the specific bandwidths of light responsible for eliciting a therapeutic response. BLUEWAVE™ allows us to increase the effective bandwidths while significantly reducing the overall intensity of light. As a result, patients can enjoy a more comfortable and efficient therapy
What is BLUEWAVE™?
The specific bandwidth of light that is responsible for suppressing melatonin and shifting circadian rhythms encompasses light in the range of 446 – 477nm (nanometers) and peaks at 464nm. This narrow slice of light is in the upper end of the blue spectrum. Apollo’s patented BLUEWAVE™ technology is the only method that delivers the effective intensity of this bandwidth of light.
How Effective Is BLUEWAVE™
Recently, the Journal of Neuroscience reported that this specific bandwidth of light is up to five timesmore effective than other wavelengths at causing this neurochemical shift. A joint National Institute of Health (NIH) study with Apollo and Thomas Jefferson University was also conducted to determine the antidepressant response of BLUEWAVE™ LED technology. This study demonstrated recovery and remission rates equal to or higher than similar studies with standard bright light therapy.
Is BLUEWAVE™ Safe?
The NIH study was conducted in accordance with FDA guidelines for ocular safety. Dr. David Sliney, the NIH physicist responsible for ocular safety testing, reported that BLUEWAVE™was well below Governmental threshold levels for ocular safety. Since the risk of ocular damage diminishes exponentially with increasing wavelength (AACGIH, 2001) BLUEWAVE™ poses no risk of ocular damage (Ocular damage occurs in the range of 340 – 390 nm, ultraviolet and near ultraviolet light). Also because BLUEWAVE™technology is very targeted, it produces no UV emissions.
No Reported Side Effects
At the annual Society for Light Treatment and Biological Rhythms convention in May 2004, TMJU researchers reported their latest study using Apollo’s BLUEWAVE™ technology. Not only were response and remission rates equivalent to standard 10,000-lux studies, but no side effects were reported from using BLUEWAVE™ These findings were remarkable, especially considering that previous 10,000-lux light therapy studies had participants who experienced initial side effects ranging from nausea to headaches.
In addition, participants remarked that their therapy was more comfortable than 10,000-lux light therapy, and when given a choice, preferred using BLUEWAVE™. Some patients who used 10,000-lux light therapy remarked that BLUEWAVE™ was ‘easier’ on their eyes. Under normal circumstances, light therapy studies expect some participant drop out, but the dropout rate with the BLUEWAVE™ study was far lower than normal. Researchers also noted that the participation rate unusual and encouraging.
Who Has BLUEWAVE ™Technology?
The specific bandwidth of light was discovered by Thomas Jefferson Medical University, and Apollo owns the patent applications for BLUEWAVE™ technology. BLUEWAVE™ technology was developed by Apollo to apply TJMU’s research. Although a few companies claim to have this or similar technology, they do not. Apollo Health, Inc. is the only light therapy company to have participated with TMJU in these research studies, and only Apollo is authorized to research and manufacture devices with BLUEWAVE™ technology.
Published Studies on 470 nm Short Wavelength Light
• Light Therapy for Seasonal Affective Disorder with 470 nm Narrow-Band Light-Emitting Diodes (LEDs), Chronobiology International 21/4-5/2004, 783.
• Action spectrum for melatonin regulation in humans: evidence for a novel circadian photoreceptor, J Neurosci. 2001 Aug 15;21(16):6405-12
• High sensitivity of the human circadian melatonin rhythm to resetting by short wavelength light, J Clin Endocrinol Metabol 2003 Sep;88(9):4502-5.
• Differential effects of light wavelength in phase advancing the melatonin rhythm, J Pineal Research. March 2004; 36 (2): 140-4
• An action spectrum for melatonin suppression: evidence for a novel non-rod, non-cone photoreceptor system in humans.J Physiol. 2001 Aug 15;535(Pt 1):261-7.
• Phase advancing human circadian rhythms with short wavelength light, Neurosci Lett. 2003 May 15;342(1-2):37-40
• Optimization of light and melatonin to phase-shift human circadian rhythms, J Neuroendocrinol. 2003 Apr;15(4):438-41
• LRC Studies Human Response to Light, Discovers Evidence of Mechanism Leading to Melatonin Suppression, Lighting Research Center News, April 6, 2004 http://news.rpi.edu/